Publications by authors named "Isabelle Monnet"

Claim this Profile
R
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Antoine Bronstein, Hubert Curcio, Isabelle Monnet, Charles Ricordel, Laurence Bigay-Game

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
Jessica Menis, Laurent Greiller, Pierre Demontrond, Isabelle Monnet, Silvia Novello

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.
Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, Solenn Brosseau, Claire Danel, Isabelle Monnet

Transl Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Isabelle Monnet

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".
Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Isabelle Monnet

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Isabelle Monnet

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, Clara Morin, Marie Wislez

Oncologist· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Arianna Marinello, Maria Rosa Ghigna, Julia K Rotow, Tolulope Adeyelu, Giulio Metro, Isabelle Monnet

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
Elisa Gobbini, Alexandra Langlais, Pascale Missy, Sébastien Chanoine, Benjamin Besse, Isabelle Monnet

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.
Charu Aggarwal, Alex Martinez-Marti, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Isabelle Monnet

JAMA Netw Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study).
Florent Vinas, Hélène Goussault, Laurent Boyer, Gaëlle Rousseau Bussac, Laurence Jabot, Isabelle Monnet

Lung Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Hervé Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, Isabelle Monnet

Lancet Respir Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Isabelle Monnet

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
Filippo G Dall'Olio, Wael Zrafi, Veronique Roelants, Valentina Ambrosini, Aloyse Fourquet, Isabelle Monnet

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report.
Julie Lasvergnas, Isabelle Monnet, Jean-Bernard Auliac, Gaelle Rousseau-Bussac, Christos Chouaid

Transl Lung Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.
Gaspard Naulleau, Isabelle Monnet, Gaëlle Rousseau-Bussac, Florent Vinas, Gilles Mangiapan

Transl Lung Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Gary Birsen, Valérie Gounant, Nicolas Girard, Jacques Cadranel, Isabelle Monnet

Transl Lung Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice.
Simon Garinet, Audrey Lupo, Thomas Denize, Romain Loyaux, Sarah Timsit, Isabelle Monnet

Pathology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
Mathilde Jacob, Pierre Fournel, Claire Tissot, Jacques Cadranel, Olivier Bylicki, Isabelle Monnet

Lung Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, Ana Callejo, Kamal Al-Rabi, Isabelle Monnet

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.
Helene Doubre, Isabelle Monnet, Reza Azarian, Philippe Girard, Guy Meyer

Res Pract Thromb Haemost· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, Lise Boussemart, Jean Chiesa, Isabelle Monnet

PLoS One· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Guénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, Christian Creveuil, Solenn Brosseau, Isabelle Monnet

Lung Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line management of advanced non-small-cell lung cancer: can we do better?
Christos Chouaïd, Isabelle Monnet, Jean-Bernard Auliac

Transl Lung Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, Acya Bizieux, Hubert Curcio

Lung Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis